| Name | Title | Contact Details |
|---|---|---|
Ling Zeng |
Chief Legal and Administrative Officer | Profile |
Jeffrey Kopacz |
Vice President, Intellectual Property | Profile |
Asterias Biotherapeutics is a leading biotechnology company in the emerging field of regenerative medicine. The company’s proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of oncology and neurology.
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company`s proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.
Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development. Our mission is to help people see life better through medicine.
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients. In addition, MannKind is applying our novel technologies and services to support partner development efforts.
Precision Diagnostics, a leader in clinical laboratory testing and medication adherence monitoring, is transforming healthcare through the delivery of comprehensive, insightful clinical data that can help improve patient outcomes and manage costs. Spec...